相关实验视频
Updated: Jun 6, 2026
02:26
Intracranial Pharmacotherapy and Pain Assays in Rodents
Published on: April 9, 2019
通过抑制前带带皮层中的PKMzeta来缓解神经性疼痛过敏
Xiang-Yao Li1, Hyoung-Gon Ko, Tao Chen
1Department of Physiology, Faculty of Medicine, Center for the Study of Pain, University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada.
Science (New York, N.Y.)
|December 4, 2010
概括
在前环皮质 (ACC) 中的蛋白质激酶M zeta (PKMζ) 维持慢性疼痛. 抑制PKMζ消除了与疼痛相关的突触变化,并阻止了行为敏感化,这表明PKMζ是治疗目标.
科学领域:
- 神经科学是一个神经科学.
- 疼痛研究 疼痛研究
- 分子生物学分子生物学
背景情况:
- 突触可塑性对于中枢神经系统中慢性疼痛的发展至关重要.
- 研究主要集中在塑料变化的触发因素上,对其维护的关注较少.
- 特定信号蛋白在维持慢性疼痛状态中的作用仍在研究中.
研究的目的:
- 研究蛋白激酶M zeta (PKMζ) 在维持疼痛诱导的突触可塑性的作用.
- 为了确定前带带皮层 (ACC) 中的PKMζ是否与神经病痛的持续性有关.
- 评估PKMζ作为慢性疼痛的潜在治疗点.
主要方法:
- 在小鼠中诱导周围神经损伤以模拟神经病痛.
- 测量神经损伤后在ACC中PKMζ激活.
- 选择性PKMζ抑制剂 (z-pseudosubstrate抑制,ZIP) 通过微注射到ACC.
- 评估ZIP对突触强化和行为敏感化的影响.
主要成果:
- 周围神经损伤导致PKMζ在ACC中的激活增加.
- 通过ZIP抑制PKMζ可以逆转ACC中已建立的突触强化.
- 将ZIP微注射到ACC中成功地阻止了与神经病痛相关的行为敏感化.
结论:
- 在ACC中的PKMζ在维持导致慢性神经病痛的突触变化方面发挥着至关重要的作用.
- 在ACC中准PKMζ为开发慢性疼痛新疗法提供了一个有希望的策略.
- 这些发现强调了在慢性疼痛管理中解决突触可塑性的维持机制的重要性.
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...